HC Wainwright Forecasts Talphera’s Q3 Earnings (NASDAQ:TLPH)

Talphera, Inc. (NASDAQ:TLPH) – Investment analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for Talphera in a report issued on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.06) per share for the quarter, up from their previous estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Talphera’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Talphera’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.17) EPS.

Talphera (NASDAQ:TLPH) last announced its earnings results on Thursday, August 13th. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06).

TLPH has been the subject of a number of other reports. Westpark Capital started coverage on shares of Talphera in a research note on Thursday, April 30th. They issued a “buy” rating and a $3.00 target price for the company. Wall Street Zen raised shares of Talphera to a “hold” rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Talphera to a “hold” rating in a research report on Monday, June 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.00.

Talphera Stock Down 2.4%

Shares of NASDAQ TLPH opened at $1.20 on Monday. Talphera has a 12-month low of $0.40 and a 12-month high of $1.57. The firm’s 50-day simple moving average is $1.20 and its 200 day simple moving average is $0.96. The company has a market cap of $62.28 million, a price-to-earnings ratio of -4.44 and a beta of 0.69.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Cantor Fitzgerald L. P. acquired a new stake in shares of Talphera during the 4th quarter worth approximately $658,000. Diadema Partners LP acquired a new position in Talphera in the fourth quarter valued at approximately $156,000. Persistent Asset Partners Ltd acquired a new position in Talphera in the fourth quarter valued at approximately $42,000. Mariner LLC boosted its stake in Talphera by 132.0% in the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after acquiring an additional 33,000 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Talphera by 412.6% in the fourth quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock valued at $293,000 after acquiring an additional 207,166 shares during the last quarter. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.